Zacks: ASLAN PHARMACEUTICALS ADR REP 5 (ASLN) Receives Consensus Recommendation of “Buy” from Brokerages

Share on StockTwits

ASLAN PHARMACEUTICALS ADR REP 5 (NASDAQ:ASLN) has earned a consensus broker rating score of 1.50 (Buy) from the four brokers that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a hold rating and three have given a strong buy rating to the company.

Brokers have set a 12 month consensus price objective of $12.25 for the company and are predicting that the company will post ($0.34) earnings per share for the current quarter, according to Zacks. Zacks has also given ASLAN PHARMACEUTICALS ADR REP 5 an industry rank of 98 out of 255 based on the ratings given to related companies.

ASLN has been the topic of several recent analyst reports. HC Wainwright initiated coverage on shares of ASLAN PHARMACEUTICALS ADR REP 5 in a research report on Wednesday, May 30th. They set a “buy” rating and a $12.00 target price on the stock. BTIG Research initiated coverage on shares of ASLAN PHARMACEUTICALS ADR REP 5 in a research report on Wednesday, May 30th. They set a “buy” rating and a $16.00 target price on the stock. Zacks Investment Research upgraded shares of ASLAN PHARMACEUTICALS ADR REP 5 from a “hold” rating to a “buy” rating and set a $8.75 target price on the stock in a research report on Tuesday, July 31st. Leerink Swann initiated coverage on shares of ASLAN PHARMACEUTICALS ADR REP 5 in a research report on Wednesday, May 30th. They set a “market perform” rating and a $7.00 target price on the stock. Finally, Piper Jaffray Companies initiated coverage on shares of ASLAN PHARMACEUTICALS ADR REP 5 in a research report on Wednesday, May 30th. They set an “overweight” rating on the stock.

Hedge funds and other institutional investors have recently made changes to their positions in the business. MYDA Advisors LLC purchased a new stake in shares of ASLAN PHARMACEUTICALS ADR REP 5 in the second quarter valued at about $195,000. Platinum Investment Management Ltd. purchased a new stake in shares of ASLAN PHARMACEUTICALS ADR REP 5 in the second quarter valued at about $2,532,000. Finally, Temasek Holdings Private Ltd purchased a new stake in shares of ASLAN PHARMACEUTICALS ADR REP 5 in the second quarter valued at about $12,660,000. 10.93% of the stock is currently owned by institutional investors.

Shares of ASLAN PHARMACEUTICALS ADR REP 5 stock traded down $0.14 on Thursday, reaching $7.66. 1,193 shares of the stock were exchanged, compared to its average volume of 3,673. ASLAN PHARMACEUTICALS ADR REP 5 has a 1-year low of $5.08 and a 1-year high of $10.44.

ASLAN PHARMACEUTICALS ADR REP 5 (NASDAQ:ASLN) last issued its earnings results on Monday, August 6th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.06). equities analysts anticipate that ASLAN PHARMACEUTICALS ADR REP 5 will post -1.36 earnings per share for the current fiscal year.

About ASLAN PHARMACEUTICALS ADR REP 5

ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, develops therapeutics for the treatment cancer in Asia, the United States, Europe, and internationally. The company's product pipeline includes Varlitinib, a novel agent, which has completed Phase II studies in gastric and breast cancer, and entered into pivotal studies for biliary tract cancer; ASLAN002, a potent cMET and Recepteur d'Origine Nantais (RON) inhibitor that is in Phase II development for the treatment of gastric and breast cancer; and ASLAN003, a novel DHODH inhibitor, which is in Phase I clinical trials to treat acute myeloid leukemia and solid tumors.

Further Reading: How Do You Calculate Return on Equity (ROE)?

Get a free copy of the Zacks research report on ASLAN PHARMACEUTICALS ADR REP 5 (ASLN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ASLAN PHARMACEUTICALS ADR REP 5 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEUTICALS ADR REP 5 and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.